SCHEMBL20047504

SCHEMBL20047504

CC(C)c1ccc2nc(C(C)(C)C)ncc2c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.38
RAB9A P51151 3/20 0.38
SCN4A P35499 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
PSMB5 P28074 1/20 0.36
PDE10A Q9Y233 1/20 0.35
TYR P14679 1/20 0.34
SCN10A Q9Y5Y9 1/20 0.33
BRAF P15056 2/20 0.32
LMNA P02545 1/20 0.32
MEN1 O00255 2/20 0.31
KMT2A Q03164 2/20 0.31
ALDH1A1 P00352 2/20 0.31
KDM4E B2RXH2 1/20 0.31
TP53 P04637 1/20 0.31
MAPT P10636 1/20 0.31
HSD17B10 Q99714 1/20 0.31
ADORA2A P29274 1/20 0.31
ADORA1 P30542 1/20 0.31
TRPA1 O75762 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14328084 0.88 BRAF (0.38) RAB9ABRAFMAPT
SCHEMBL20047524 0.87 CYP17A1 (0.30) ADORA2AADORA1
SCHEMBL13310575 0.85 NPC1 (0.37) NPC1RAB9ASCN4ASMN1; SMN2PSMB5
SCHEMBL888951 0.77 NPC1 (0.41) NPC1RAB9ASCN4ASMN1; SMN2PSMB5
SCHEMBL4548606 0.77 SCN10A (0.39) PDE10ASCN10AMEN1KMT2AALDH1A1
SCHEMBL799309 0.77 PSMB5 (0.41) NPC1RAB9ASCN4ASMN1; SMN2PSMB5
SCHEMBL25994286 0.76 ABL1 (0.40) NPC1RAB9ASMN1; SMN2PDE10ALMNA
SCHEMBL27998998 0.76 NPC1 (0.40) NPC1RAB9ASCN4ASMN1; SMN2PSMB5
SCHEMBL2625324 0.76 LCK (0.49) NPC1RAB9ASCN4ASMN1; SMN2PSMB5
SCHEMBL10220264 0.76 BACE1 (0.42) SMN1; SMN2PSMB5LMNAALDH1A1ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10689391-B2 Isoxazole analogs as FXR agonists and methods of use thereof ENANTA PHARMACEUTICALS, INC. (US) 2020-06-23 US disclosed
US-10450306-B2 Isoxazole analogs as FXR agonists and methods of use thereof ENANTA PHARMACEUTICALS, INC. (US) 2019-10-22 US disclosed
US-20190194216-A1 ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2019-06-27 US disclosed
US-20180099957-A1 ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2018-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10450306-B2 Isoxazole analogs as FXR agonists and methods of use thereof GPBAR1, SLC10A1, NR1H4 NPC1 52/4885RAB9A 2692/4885SCN4A 3314/4885
US-20180099957-A1 ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF GPBAR1, SLC10A1, NR1H4 NPC1 52/4885RAB9A 2692/4885SCN4A 3314/4885
US-20190194216-A1 ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF SLC10A1, NR1H4, GPBAR1 NPC1 56/4885RAB9A 2307/4885SCN4A 3134/4885
US-10689391-B2 Isoxazole analogs as FXR agonists and methods of use thereof SLC10A1, NR1H4, GPBAR1 NPC1 56/4885RAB9A 2307/4885SCN4A 3134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.